Back to Results

Lyra Therapeutics Inc (LYRA)

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company listed on OTC Markets as common stock. The company is developing therapies for chronic rhinosinusitis, with a focus on anti-inflammatory treatments. Its delivery approach is designed to place medicine at the target tissue and provide extended exposure from a single administration. Lyra’s pipeline includes LYR-210, an implantable drug matrix in Phase III testing for chronic rhinosinusitis, and LYR-220, which is being studied for patients who have not responded adequately to prior medical therapy. The company also has a collaboration with LianBio Inflammatory Limited covering development and commercialization rights for LYR-210 in several Asian markets, including mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. Founded in 2005, Lyra Therapeutics is headquartered in Watertown, Massachusetts, and previously operated under the name 480 Biomedical, Inc.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
OTC-LYRA
$0.23
17.5% Upside
Fair
$16 7,900.0% Upside
Not available
Bargain
Weak
0.0%
0.9x
354.976 K
14.721 M
98.8%
24.8%
-19.3
100.2%
Valuation • Fair Value

Lyra Therapeutics Inc (OTC-LYRA) Fair Value by Valuation Model

Review the available estimates for Lyra Therapeutics Inc (OTC-LYRA), including Comps Fair Value.

Primary Valuation Read

Fair Value

$0.23

Estimated upside of 17.5% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$0.23

Comparable-company valuation reference.

Analyst Price Target

$16 7,900.0% Upside

Current consensus analyst target, where available.

How to read these valuation models

Use the 4 available valuation references for Lyra Therapeutics Inc (OTC-LYRA) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Lyra Therapeutics Inc (OTC-LYRA)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

398 K

Current operating scale indicator.

Revenue Forecast

700 K

Forward revenue estimate.

EBITDA

-29.094 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Lyra Therapeutics Inc (OTC-LYRA) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Lyra Therapeutics Inc (OTC-LYRA)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

2

Weak quality score that deserves closer review.

Altman Z-Score

-19.3

Lower score that deserves closer risk review.

FCF / Net Income

100.2%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Lyra Therapeutics Inc (OTC-LYRA). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for Lyra Therapeutics Inc (OTC-LYRA)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for Lyra Therapeutics Inc (OTC-LYRA). No upcoming dividend amount or event date is currently available.

Stock Forecast • Technical Outlook

Lyra Therapeutics Inc (OTC-LYRA) Stock Forecast & Technical Outlook

Review Lyra Therapeutics Inc (OTC-LYRA) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Buy

The 15-minute technical read for Lyra Therapeutics Inc (OTC-LYRA) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Lyra Therapeutics Inc (OTC-LYRA) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Lyra Therapeutics Inc (OTC-LYRA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Lyra Therapeutics Inc (OTC-LYRA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Lyra Therapeutics Inc (OTC-LYRA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Lyra Therapeutics Inc (OTC-LYRA)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Lyra Therapeutics Inc (OTC-LYRA) has a Hold consensus, with 0 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 0
Hold 1
Sell 0
FAQ • Fast Investor Answers

Lyra Therapeutics Inc (OTC-LYRA) Stock FAQ

Data-supported answers about Lyra Therapeutics Inc (OTC-LYRA), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.23
Estimated upside 17.5%
Valuation Rating
Undervalued
Estimated upside of 17.5%
Analyst Target
$16 7,900.0% Upside
Data is currently unavailable
Financial Health
Weak
Current financial-health read

The current fair value estimate for Lyra Therapeutics Inc (OTC-LYRA) is $0.23. This implies an estimated upside of 17.5% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 17.5% versus the current market price.

The available analyst price target for Lyra Therapeutics Inc (OTC-LYRA) is $16 7,900.0% Upside.

The current financial health read for Lyra Therapeutics Inc (OTC-LYRA) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for Lyra Therapeutics Inc (OTC-LYRA).

The current market capitalization listed for Lyra Therapeutics Inc is 354.976 K.

The current enterprise value listed for Lyra Therapeutics Inc is 14.721 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Lyra Therapeutics Inc is OTC-LYRA, and the stock is listed on OTC Markets.

Lyra Therapeutics Inc (OTC-LYRA) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Lyra Therapeutics Inc is 98.8%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Lyra Therapeutics Inc is 24.8%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,043 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 648.7 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 372.3 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 269.8 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 175.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 159.2 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 127.2 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 102 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.536 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 46.053 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.268 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.639 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 30.107 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.733 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.616 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Overvalued Market Cap 12.702 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.456 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.639 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.564 B